Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

A. Chiappella; M. Martelli; E. Angelucci; E. Brusamolino; A. Evangelista; A.M. Carella; C. Stelitano; G. Rossi; M. Balzarotti; F. Merli; G. Gaidano; V. Pavone; L. Rigacci; F. Zaja; A. D'Arco; N. Cascavilla; E. Russo; A. Castellino; M. Gotti; A.G. Congiu; M.G. Cabras; A. Tucci; C. Agostinelli; G. Ciccone; S.A. Pileri; U. Vitolo

doi:10.1016/S1470-2045(17)30444-8

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

A. Chiappella, M. Martelli, E. Angelucci, E. Brusamolino, A. Evangelista, A.M. Carella, C. Stelitano, G. Rossi, M. Balzarotti, F. Merli, G. Gaidano, V. Pavone, L. Rigacci, F. Zaja, A. D'Arco, N. Cascavilla, E. Russo, A. Castellino, M. Gotti, A.G. CongiuM.G. Cabras, A. Tucci, C. Agostinelli, G. Ciccone, S.A. Pileri, U. Vitolo

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1076-1088
Number of pages	13
Journal	The Lancet Oncology
Volume	18
Issue number	8
DOIs	https://doi.org/10.1016/S1470-2045(17)30444-8
Publication status	Published - 2017

Access to Document

10.1016/S1470-2045(17)30444-8

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021347992&doi=10.1016%2fS1470-2045%2817%2930444-8&partnerID=40&md5=504f950ff333463e816b5f46b3148018

Cite this

Chiappella, A., Martelli, M., Angelucci, E., Brusamolino, E., Evangelista, A., Carella, A. M., Stelitano, C., Rossi, G., Balzarotti, M., Merli, F., Gaidano, G., Pavone, V., Rigacci, L., Zaja, F., D'Arco, A., Cascavilla, N., Russo, E., Castellino, A., Gotti, M., ... Vitolo, U. (2017). Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. The Lancet Oncology, 18(8), 1076-1088. https://doi.org/10.1016/S1470-2045(17)30444-8

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. / Chiappella, A.; Martelli, M.; Angelucci, E.; Brusamolino, E.; Evangelista, A.; Carella, A.M.; Stelitano, C.; Rossi, G.; Balzarotti, M.; Merli, F.; Gaidano, G.; Pavone, V.; Rigacci, L.; Zaja, F.; D'Arco, A.; Cascavilla, N.; Russo, E.; Castellino, A.; Gotti, M.; Congiu, A.G.; Cabras, M.G.; Tucci, A.; Agostinelli, C.; Ciccone, G.; Pileri, S.A.; Vitolo, U.

In: The Lancet Oncology, Vol. 18, No. 8, 2017, p. 1076-1088.

Research output: Contribution to journal › Article › peer-review

Chiappella, A, Martelli, M , Angelucci, E, Brusamolino, E, Evangelista, A, Carella, AM, Stelitano, C, Rossi, G , Balzarotti, M , Merli, F, Gaidano, G, Pavone, V, Rigacci, L, Zaja, F, D'Arco, A, Cascavilla, N, Russo, E, Castellino, A, Gotti, M, Congiu, AG, Cabras, MG, Tucci, A, Agostinelli, C, Ciccone, G, Pileri, SA & Vitolo, U 2017, 'Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study', The Lancet Oncology, vol. 18, no. 8, pp. 1076-1088. https://doi.org/10.1016/S1470-2045(17)30444-8

Chiappella A, Martelli M , Angelucci E, Brusamolino E, Evangelista A, Carella AM et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. The Lancet Oncology. 2017;18(8):1076-1088. https://doi.org/10.1016/S1470-2045(17)30444-8

Chiappella, A. ; Martelli, M. ; Angelucci, E. ; Brusamolino, E. ; Evangelista, A. ; Carella, A.M. ; Stelitano, C. ; Rossi, G. ; Balzarotti, M. ; Merli, F. ; Gaidano, G. ; Pavone, V. ; Rigacci, L. ; Zaja, F. ; D'Arco, A. ; Cascavilla, N. ; Russo, E. ; Castellino, A. ; Gotti, M. ; Congiu, A.G. ; Cabras, M.G. ; Tucci, A. ; Agostinelli, C. ; Ciccone, G. ; Pileri, S.A. ; Vitolo, U. / Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. In: The Lancet Oncology. 2017 ; Vol. 18, No. 8. pp. 1076-1088.

@article{6e8fd7505ec84efd9bb54ab16e2d2448,

title = "Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study",

author = "A. Chiappella and M. Martelli and E. Angelucci and E. Brusamolino and A. Evangelista and A.M. Carella and C. Stelitano and G. Rossi and M. Balzarotti and F. Merli and G. Gaidano and V. Pavone and L. Rigacci and F. Zaja and A. D'Arco and N. Cascavilla and E. Russo and A. Castellino and M. Gotti and A.G. Congiu and M.G. Cabras and A. Tucci and C. Agostinelli and G. Ciccone and S.A. Pileri and U. Vitolo",

note = "Cited By :4 Export Date: 2 March 2018",

year = "2017",

doi = "10.1016/S1470-2045(17)30444-8",

language = "English",

volume = "18",

pages = "1076--1088",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "8",

}

TY - JOUR

T1 - Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

AU - Chiappella, A.

AU - Martelli, M.

AU - Angelucci, E.

AU - Brusamolino, E.

AU - Evangelista, A.

AU - Carella, A.M.

AU - Stelitano, C.

AU - Rossi, G.

AU - Balzarotti, M.

AU - Merli, F.

AU - Gaidano, G.

AU - Pavone, V.

AU - Rigacci, L.

AU - Zaja, F.

AU - D'Arco, A.

AU - Cascavilla, N.

AU - Russo, E.

AU - Castellino, A.

AU - Gotti, M.

AU - Congiu, A.G.

AU - Cabras, M.G.

AU - Tucci, A.

AU - Agostinelli, C.

AU - Ciccone, G.

AU - Pileri, S.A.

AU - Vitolo, U.

N1 - Cited By :4 Export Date: 2 March 2018

PY - 2017

Y1 - 2017

U2 - 10.1016/S1470-2045(17)30444-8

DO - 10.1016/S1470-2045(17)30444-8

M3 - Article

VL - 18

SP - 1076

EP - 1088

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 8

ER -